BRPI0916884A2 - composição imunogênica, processo para preparar uma composição imunogênica, uso de uma composição imunogênica, e, kit - Google Patents
composição imunogênica, processo para preparar uma composição imunogênica, uso de uma composição imunogênica, e, kitInfo
- Publication number
- BRPI0916884A2 BRPI0916884A2 BRPI0916884A BRPI0916884A BRPI0916884A2 BR PI0916884 A2 BRPI0916884 A2 BR PI0916884A2 BR PI0916884 A BRPI0916884 A BR PI0916884A BR PI0916884 A BRPI0916884 A BR PI0916884A BR PI0916884 A2 BRPI0916884 A2 BR PI0916884A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunogenic composition
- kit
- preparing
- immunogenic
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15071—Demonstrated in vivo effect
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9258208P | 2008-08-28 | 2008-08-28 | |
US9574708P | 2008-10-15 | 2008-10-15 | |
US16568809P | 2009-04-01 | 2009-04-01 | |
PCT/EP2009/060967 WO2010023216A1 (en) | 2008-08-28 | 2009-08-26 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0916884A2 true BRPI0916884A2 (pt) | 2016-06-14 |
Family
ID=41338517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0916884A BRPI0916884A2 (pt) | 2008-08-28 | 2009-08-26 | composição imunogênica, processo para preparar uma composição imunogênica, uso de uma composição imunogênica, e, kit |
Country Status (13)
Country | Link |
---|---|
US (1) | US8846080B2 (pt) |
EP (1) | EP2328613A1 (pt) |
JP (2) | JP5769624B2 (pt) |
KR (1) | KR20110050531A (pt) |
CN (1) | CN102202689A (pt) |
AU (1) | AU2009286769A1 (pt) |
BR (1) | BRPI0916884A2 (pt) |
CA (1) | CA2734950A1 (pt) |
EA (1) | EA201100268A1 (pt) |
IL (1) | IL211233A0 (pt) |
MX (1) | MX2011002267A (pt) |
WO (1) | WO2010023216A1 (pt) |
ZA (1) | ZA201101481B (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8431136B2 (en) * | 2005-06-27 | 2013-04-30 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
CN103957939A (zh) * | 2011-09-19 | 2014-07-30 | 约翰霍普金斯大学 | 癌症免疫治疗 |
KR102090740B1 (ko) * | 2011-10-03 | 2020-03-18 | 엠엑스 아쥬바크 에이비 | 암 치료 및 식품 관련 화합물을 포함하는 의학 분야에서 양친매성 또는 소수성 분자를 위한 나노입자, 제조 방법 및 담체로의 용도 |
GB201120000D0 (en) * | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
WO2013110030A2 (en) | 2012-01-19 | 2013-07-25 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
WO2015126502A2 (en) | 2013-12-03 | 2015-08-27 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
CN106535876B (zh) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | 免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用 |
EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
WO2016007504A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
RU2017129818A (ru) | 2015-02-26 | 2019-03-28 | Тевакс Дженетикс Вэксин Ко., Лтд. | Композиция вакцины, содержащая иммуногенный белок и комбинированные адъюванты, для применения в стимулировании антигенспецифичных т-клеточных ответов |
AU2016332266B2 (en) * | 2015-09-30 | 2020-05-07 | Shionogi & Co., Ltd. | Nucleic acid derivative having immunostimulatory activity |
US10940201B2 (en) | 2015-09-30 | 2021-03-09 | Shionogi & Co., Ltd. | Nucleic acid derivative having immunostimulatory activity |
CN108697779B (zh) | 2016-01-07 | 2023-09-19 | 杜克大学 | 癌症疫苗和递送方法 |
JP7195147B2 (ja) * | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Peg化リポソームおよび使用方法 |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
US10058606B2 (en) | 2016-09-19 | 2018-08-28 | Thevax Genetics Vaccine Co., Ltd. | Hepatitis B therapeutic vaccines |
US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
SG11201908059YA (en) * | 2017-03-29 | 2019-10-30 | Shionogi & Co | Nucleic acid derivative having immunostimulatory activity |
KR20200028997A (ko) | 2017-07-13 | 2020-03-17 | 노오쓰웨스턴 유니버시티 | 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법 |
CN111551729B (zh) * | 2020-04-27 | 2021-02-09 | 浙江正熙生物技术股份有限公司 | 藻红蛋白免疫荧光探针制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2423335B1 (en) * | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same |
US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
AU2004219910B2 (en) * | 2003-03-13 | 2010-06-17 | Glaxosmithkline Biologicals S.A. | Purification process for bacterial cytolysin |
AU2004275876B2 (en) * | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
KR101138131B1 (ko) * | 2003-12-08 | 2012-04-23 | 이데라 파마슈티칼즈, 인코포레이티드 | 작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절 |
CA2574090A1 (en) * | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
WO2006066003A2 (en) * | 2004-12-17 | 2006-06-22 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
US8431136B2 (en) * | 2005-06-27 | 2013-04-30 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
-
2009
- 2009-08-26 JP JP2011524363A patent/JP5769624B2/ja not_active Expired - Fee Related
- 2009-08-26 EA EA201100268A patent/EA201100268A1/ru unknown
- 2009-08-26 EP EP09782191A patent/EP2328613A1/en not_active Withdrawn
- 2009-08-26 AU AU2009286769A patent/AU2009286769A1/en not_active Abandoned
- 2009-08-26 WO PCT/EP2009/060967 patent/WO2010023216A1/en active Application Filing
- 2009-08-26 US US13/060,301 patent/US8846080B2/en not_active Expired - Fee Related
- 2009-08-26 KR KR1020117006905A patent/KR20110050531A/ko not_active Application Discontinuation
- 2009-08-26 CA CA2734950A patent/CA2734950A1/en active Pending
- 2009-08-26 CN CN2009801437446A patent/CN102202689A/zh active Pending
- 2009-08-26 MX MX2011002267A patent/MX2011002267A/es not_active Application Discontinuation
- 2009-08-26 BR BRPI0916884A patent/BRPI0916884A2/pt not_active IP Right Cessation
-
2011
- 2011-02-15 IL IL211233A patent/IL211233A0/en unknown
- 2011-02-24 ZA ZA2011/01481A patent/ZA201101481B/en unknown
-
2015
- 2015-04-09 JP JP2015079662A patent/JP2015163617A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EA201100268A1 (ru) | 2011-10-31 |
JP2012500827A (ja) | 2012-01-12 |
KR20110050531A (ko) | 2011-05-13 |
ZA201101481B (en) | 2012-07-25 |
EP2328613A1 (en) | 2011-06-08 |
US8846080B2 (en) | 2014-09-30 |
MX2011002267A (es) | 2011-03-30 |
CN102202689A (zh) | 2011-09-28 |
WO2010023216A1 (en) | 2010-03-04 |
JP2015163617A (ja) | 2015-09-10 |
IL211233A0 (en) | 2011-04-28 |
US20110159081A1 (en) | 2011-06-30 |
CA2734950A1 (en) | 2010-03-04 |
AU2009286769A1 (en) | 2010-03-04 |
JP5769624B2 (ja) | 2015-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0916884A2 (pt) | composição imunogênica, processo para preparar uma composição imunogênica, uso de uma composição imunogênica, e, kit | |
BR112013014598A2 (pt) | composição imunogênica, uso de uma composição imunogênica, processo para preparar uma composição imunogênica, método para a fabricação de uma composição imunogênica estável, e, kit | |
BRPI0921399A2 (pt) | composição de graxa lubrificante, processo para preparar composição lubrificante, e, uso de uma composição de graxa lubrificante | |
BRPI0920955A2 (pt) | processo para a preparação de uma composição polimérica , composição polimérica, misturas, e, uso da composição polimérica | |
BRPI0911297A2 (pt) | composição e métodos para preparo e uso das mesmas | |
BRPI1012890A2 (pt) | composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit | |
BRPI0822104A2 (pt) | Composições antimicrobianas e métodos para o uso das mesmas | |
BRPI0919192A2 (pt) | Uso de lipídio, composição nutricional, e, processo para a produção de uma composição nutricional | |
BRPI1010775A2 (pt) | composição, método para preparar uma composição, e, uso de uma composição. | |
BRPI0918487A2 (pt) | processo para a preparação de uma composição de copolímero, composição, e, uso de uma composição de copolímero | |
BRPI0814611A2 (pt) | Composição, processo para preparar uma composição, e, uso de uma composição | |
BRPI0920263A2 (pt) | composto, uso do composto, composição, e, método | |
BRPI0918359A2 (pt) | composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto | |
BRPI0912703A2 (pt) | composições imuno-moduladoras e métodos para uso dessas | |
BRPI1014800A8 (pt) | "composição compreendendo alfa-(1,6) oligodextranas alfa-(1,2) ramificadas, método para preparar as referidas oligodextranas e uso das mesmas" | |
BRPI0916110A2 (pt) | "processo para preparação do co-precipitado, co-precipitado e kit para preparar um implante osteogênico" | |
BRPI0907663A8 (pt) | composição que compreende hfo- 123 yf, composição que compreende hcfc-243db, composição que compreende hcfo- 1233xf, composição que comproeende hcfc- 244bb, uso das composições e método de uso das composições | |
BRPI0911815A2 (pt) | estrutura de multifilme, estrutura de envelope feita de uma estrutura de multifilme, uso de uma estrutura de multifilme e processo para preparar uma estrutura de multifilme | |
BRPI0813627A2 (pt) | Peptídio antimicrobiano, composições e métodos de uso | |
BRPI0914343A2 (pt) | composição, produto, uso da composição e método | |
BRPI0923513A2 (pt) | método e composições para uso de uma vacina de coccidiose | |
BRPI0822946A2 (pt) | Derivado de carboxiamida, processo para preparação de derivado de carboxiamida, composição farmacêutica e uso do derivado de carboxiamida | |
BRPI0906673A2 (pt) | dispersão aquosa, processo para preparar uma dispersão aquosa, uso de uma dispersão aquosa, e, produto | |
BRPI1013051A2 (pt) | composição imunogênica, uso de uma composição imunogênica, processo para fazer uma composição imunogênica, e, kit. | |
BRPI1010617A2 (pt) | uso de uma composição, composição, uso não médico da composição, e, método para preprar uma composição. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2476 DE 19-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |